Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
RSC Adv ; 9(30): 17035-17039, 2019 May 29.
Article in English | MEDLINE | ID: mdl-35519882

ABSTRACT

The thermally and photolytically induced disproportionation of 6,13-dihydropentacene derivatives into tetrahydropentacenes and pentacenes results in unique solid-state fluorescence. The fluorescence thereby depends on the molecular structure and the molecular arrangement in the solid state.

2.
Nihon Hinyokika Gakkai Zasshi ; 98(5): 691-9, 2007 Jul.
Article in Japanese | MEDLINE | ID: mdl-17682448

ABSTRACT

PURPOSE: We compared the efficacy of naftopidil with that of tamsulosin hydrochloride for 154 symptomatic benign prostatic hyperplasia (BPH) patients who also suffered from overactive bladder (OAB) symptoms. MATERIALS AND METHODS: Naftopidil and tamsulosin hydrochloride were administered for eight weeks. The international prostate symptom score (IPSS), QOL index, maximum flow rate (Q(max)), residual urine volume (RUV) and side effect profile were determined before the administration and after eight weeks of treatment. RESULTS: In the naftopidil group, seven parameters of IPSS and QOL index were improved significantly at the endpoint compared to the baseline. In the tamsulosin group, all parameters except frequency and straining were also improved. Both drugs improved the Q(max) at the endpoint, too. The RUV did not change in both groups. Naftopidil was also superior to tamsulosin hydrochloride regarding general treatment outcome by the Japanese clinical guideline of urinary disturbance. CONCLUSIONS: This study demonstrated that naftopidil was clinically efficacious in the treatment of BPH patients with OAB.


Subject(s)
Adrenergic alpha-Antagonists/therapeutic use , Naphthalenes/therapeutic use , Piperazines/therapeutic use , Prostatic Hyperplasia/drug therapy , Quality of Life , Sulfonamides/therapeutic use , Urinary Bladder, Overactive/complications , Adult , Aged , Drug Administration Schedule , Humans , Male , Middle Aged , Prostatic Hyperplasia/physiopathology , Tamsulosin , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...